<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278378</url>
  </required_header>
  <id_info>
    <org_study_id>REC/11/0081</org_study_id>
    <nct_id>NCT04278378</nct_id>
  </id_info>
  <brief_title>Blood Pressure Lowering Effect of B-vitamins in Adults With a Genetic Pre-disposition to Elevated Blood Pressure.</brief_title>
  <acronym>RAFA</acronym>
  <official_title>Blood Pressure Lowering Effect of B-vitamins in Adults With a Genetic Pre-disposition to Elevated Blood Pressure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 12% of the world's population have a have a common C677T polymorphism in the&#xD;
      gene encoding the folate metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR).&#xD;
      Homozygosity for the polymorphism (TT genotype) causes an increased requirement for the&#xD;
      B-vitamins folic acid and riboflavin and more importantly results in an increased risk of&#xD;
      developing high blood pressure (BP). Previous work from our Centre has demonstrated&#xD;
      significantly higher BP in those with the TT genotype. This work has been conducted in&#xD;
      cohorts with premature cardiovascular disease (CVD) and hypertension without overt CVD, but&#xD;
      the effect in younger, healthier individuals is unexplored. To date our studies have also&#xD;
      focused on BP as the primary outcome, but newer markers of vascular health including central&#xD;
      pressure and hemodynamics have emerged as superior prognostic indicators of CVD. The effect&#xD;
      of the TT genotype on these measures is an area for investigation and may help us understand&#xD;
      the mechanism linking the genotype with BP, which is currently unknown. As adults with the TT&#xD;
      genotype have increased requirements for riboflavin and folic acid, and BP in TT adults&#xD;
      appears to be riboflavin dependent, the influence of these vitamins on central measures is an&#xD;
      area for consideration. Study Design This is an observational study investigating the blood&#xD;
      pressure profiles of healthy adults aged 18-65 years, stratified by MTHFR genotype.&#xD;
      Apparently healthy adults will be recruited from workplaces and the general community across&#xD;
      Northern Ireland and screened for the polymorphism via buccal swab. Those with the TT&#xD;
      genotype and a similar number of non-TT (i.e. CC/CT) genotype individuals will be contacted&#xD;
      and asked to come to a one-off appointment. Brachial BP will be assessed by an electronic BP&#xD;
      monitor, central BP and central haemodynamics (augmentation index, augmentation pressure and&#xD;
      pulse wave velocity) will be assessed by SphygmoCor XCEL. In addition, anthropometric&#xD;
      measurements, health and lifestyle infromation and a blood sample will be obtained. Data will&#xD;
      be statistically analysed using SPSS software to if determine differences between gentoype&#xD;
      groups exist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2011</start_date>
  <completion_date type="Actual">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Office blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central blood pressure</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured using SphygmoCor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured using SphygmoCor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured using SphygmoCor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell riboflavin</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured using erythrocyte glutathione reductase activity coefficient (EGRAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell folate</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured by microbiological assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum homocysteine</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured using an immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma vitamin B6</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Measured by High Performance Liquid Chromatography</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2564</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Riboflavin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.6 mg riboflavin / day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg folic acid/ day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riboflavin + Folic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>1.6 mg riboflavin / day for 24 weeks</description>
    <arm_group_label>Riboflavin</arm_group_label>
    <arm_group_label>Riboflavin + Folic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>0.4 mg folic acid / day for 24 weeks</description>
    <arm_group_label>Folic Acid</arm_group_label>
    <arm_group_label>Riboflavin + Folic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MTHFR 677TT genotype, aged at least 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking supplements containing B-vitamins&#xD;
&#xD;
          -  Pregnant or planning to conceive&#xD;
&#xD;
          -  Taking medications interfering with folate metabolism&#xD;
&#xD;
          -  Renal or gastrointestinal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Human Intervention Studies Unit, Ulster University</name>
      <address>
        <city>Coleraine</city>
        <state>Co.Londonderry</state>
        <zip>BT52 1SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Central hemodynamics</keyword>
  <keyword>Methylenetetrahydrofolate reductase (MTHFR)</keyword>
  <keyword>Folate polymorphism</keyword>
  <keyword>Riboflavin</keyword>
  <keyword>Folic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

